Search

for
Search:

GlossaryGefitinib (ZD1839)

inhibits EGFR to treat certain non-small cell lung cancers

Gefitinib, also known as Iressa, is a medication used to treat certain types of non-small cell lung cancer. It works by inhibiting the epidermal growth factor receptor (EGFR), which is involved in the growth and spread of cancer cells. By blocking this receptor, gefitinib can help slow down or stop the progression of the cancer.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 30 results

research Follicular and Epidermal Alterations in Patients Treated with ZD1839 (Iressa), an Inhibitor of the Epidermal Growth Factor Receptor

169 citations , September 2002 in “British journal of dermatology/British journal of dermatology, Supplement”

ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.

research Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor

116 citations , December 2003 in “Acta Dermato Venereologica”

Iressa often causes skin issues like acne and dryness in lung cancer patients.

research A Case of Hair Change and Acneiform Eruption Induced by ZD1839 (Iressa$^{(R)}$)

2 citations , January 2004 in “Linchuang pifuke zazhi”

research Acneiform Eruptions Caused by an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor ZD1839

1 citations , March 2004 in “Journal of the American Academy of Dermatology”

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

research Cutaneous Adverse Effects of Targeted Therapies

192 citations , January 2015 in “Journal of the American Academy of Dermatology”

Targeted cancer therapies often cause serious skin problems that need careful management.

View more "zd1839" in research →

Community Join

0 / 0 results

— no results